Managed Care
Disease
Management

Inhibiting the mTOR Pathway in Trastuzumab-Resistant, HER-2-Positive Advanced Breast Cancer Patients: BOLERO-3, Phase 3

Ruth O’Regan, MD, says that the combination of everolimus plus vinorelbine and trastuzumab may be considered an appropriate option in trastuzumab-resistant, HER-2-positive advanced breast cancer (BOLERO-3, Phase 3).

Meetings

Medical Devices Summit Boston, MA February 19–20, 2015
3rd Annual Summit to Improve Adherence and Enhance Patient Engagement Philadelphia, PA March 9–10, 2015
Value-Added Solutions for Enhanced Customer Experience Philadelphia, PA March 9, 2015